Series
Most Recent Segment
What This Means
Featuring: American Resources
March 7, 2025
Mark Jensen, CEO of American Resources Corporation and ReElement Technologies Corporation, discussed the Company’s production of rare earth elements and how American Resources is working to cost-effectively develop in-demand minerals for defense.
What This Means
What This Means provides investors with context to press releases directly from company management teams. It also provides the opportunity for companies to communicate directly to investors and elaborate on recent key news and highlight value driving milestones.
CEO Connect
CEO Connect allows investors to hear directly from company CEOs, who will provide a brief presentation followed by an interactive Q&A session. Investors and interested parties have the opportunity to submit questions live during the event.
KOL Connect
KOL Connect features a moderated, in-depth discussion with members of the management team from participating companies along with Key Opinion Leaders.
What This Means
Featuring: PalisadeBio
March 4, 2025
Dr. Joerg Heyer, Head of Translational Science and Medicine of Palisade Bio highlights preclinical data for lead product candidate, PALI-2108, for the treatment of Ulcerative Colitis (UC)
What This Means
Featuring: Sonnet BioTherapeutics
February 19, 2025
Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates
What This Means
Featuring: AIM ImmunoTech
February 11, 2025
Tom Equels, CEO of AIM ImmunoTech and Professor Casper H.J. van Eijck, MD, PhD, Pancreato-biliary Surgeon at Erasmus MC, discuss the Phase 1b/2 clinical trial involving AIM’s Ampligen® (rintatolimod) and AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) in the treatment of late-stage pancreatic cancer (“DURIPANC”)
What This Means
Featuring: Outlook Therapeutics
February 4, 2025
Dr. Jennifer Kissner, SVP Clinical Development, Discusses the 12-week Safety and Efficacy Results for NORSE EIGHT Clinical Trial
What This Means
Featuring: Sonnet BioTherapeutics
January 28, 2025
Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB® Platform Technology
What This Means
Featuring: Moleculin
January 27, 2025
Walter Klemp, CEO of Moleculin, Provides an Update on the Company’s Phase 3 Pivotal Trial of Annamycin for the Treatment of AML Patients who are Refractory to or Relapsed After Induction Therapy (R/R AML) (the “MIRACLE” trial)
What This Means
Featuring: Sonnet BioTherapeutics
January 21, 2025
Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas
What This Means
Featuring: Outlook Therapeutics
January 8, 2025
Jedd Comisky, Senior Vice President, Head of Europe, highlights the recent NICE recommendation of LYTENAVA™ (bevacizumab gamma) for the treatment of wet AMD
What This Means
Featuring Xenetic Biosciences
December 17, 2024
Reid Bissonnette, Ph.D, Executive Consultant for Translational Research and Development at Xenetic, Discusses Extension of its Research Agreement with the University of Virgina
What This Means
Featuring Sonnet BioTherapeutics
December 9, 2024
Sonnet BioTherapeutics Announces Topline Safety Data Following Successful Completion of SON-1010 Monotherapy Dose Escalation in Phase 1 SB101 Trial
KOL Connect
Featuring AIM ImmunoTech
December 6, 2024
Dr. Charles Lapp, ME/CFS Key Opinion Leader and founder of the Hunter-Hopkins Center, Discussing Results from AIM’s Phase 2 Study Evaluating the Efficacy and Safety of Ampligen® as a Potential Therapeutic for People with the Post-COVID Condition of Fatigue
What This Means
Featuring Sonnet BioTherapeutics
December 4, 2024
Sonnet BioTherapeutics Announces Publication Detailing the Discovery and Development of SON-1010, an Albumin-Binding IL-12 Fusion Protein, Demonstrating Its Mechanism of Action
What This Means
Featuring Xenetic Biosciences
November 22, 2024
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis
What This Means
Featuring Moleculin
November 14, 2024
Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025
What This Means
Featuring Sonnet BioTherapeutics
November 12, 2024
Drs. Pankaj Mohan, CEO of Sonnet, and John Cini, CSO of Sonnet, Discuss the Company’s Rrecent Issuance of a U.S. Patent Covering a Variant of IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates, SON-1400 and SON-1411
KOL Connect
Featuring CNS Pharmaceuticals
November 4, 2024
Professor Michael Weller, a Leading Neuro-oncologist who Currently serves as the Chairman of the Department of Neurology at the University Hospital in Zurich, Switzerland and as the National Coordinating Investigator for CNS Pharmaceuticals’ Potentially Pivotal Study of Berubicin, Discusses the Unmet Need in Glioblastoma Multiforme (GBM), the Current Treatment Landscape and the Potential for Berubicin to Provide a Solution for this Devasting Disease
What This Means
Featuring Autonomix Medical
October 30, 2024
Dr. Robert Schwartz, Chief Medical Officer of Autonomix Discussing Additional Findings from the 4-6 Week Follow-up Data from the First Five “Lead-in” Patients in the Company’s Ongoing Proof-of-concept Human Clinical Trial
CEO Connect
Featuring Outlook Therapeutics
October 17, 2024
Interview with Russell Trenary, President and Chief Executive Officer
KOL Connect
Featuring CNS Pharmaceuticals
October 10, 2024
Members of the CNS Management Team and leading Neuro-Oncologist and Key Opinion Leader, Dr. Samuel Goldlust Discuss the Unmet Need in Glioblastoma Multiforme (GBM) and the CNS Opportunity
What This Means
Featuring Sonnet BioTherapeutics
October 9, 2024
Sonnet BioTherapeutics Inc. Enters into Licensing Agreement with Alkem Laboratories Limited to Develop and Commercialize SON-080 for Diabetic Peripheral Neuropathy (DPN) in India
Join Us
Sign up for email alerts to stay up-to-date on the latest Virtual Investor events
By submitting this form, you are consenting to receive marketing emails from: Virtual Investor. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact